Absent estrogen receptor and increased recurrence rate in breast cancer

W. Knight, Robert B Livingston, E. J. Gregory, W. L. McGuire

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17%): 11/34 ER- and 8/79 ER+ pts., (32 vs 10%, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34%); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42%); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20%). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17%) as in Stage II, ER+ pts. (5/33 or 15%). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.

Original languageEnglish (US)
Title of host publicationProceedings of the American Association for Cancer Research
VolumeVol. 18
StatePublished - 1977
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Recurrence
Mastectomy
Radiotherapy
Radical Mastectomy
Estrogen Receptor alpha

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Knight, W., Livingston, R. B., Gregory, E. J., & McGuire, W. L. (1977). Absent estrogen receptor and increased recurrence rate in breast cancer. In Proceedings of the American Association for Cancer Research (Vol. Vol. 18)

Absent estrogen receptor and increased recurrence rate in breast cancer. / Knight, W.; Livingston, Robert B; Gregory, E. J.; McGuire, W. L.

Proceedings of the American Association for Cancer Research. Vol. Vol. 18 1977.

Research output: Chapter in Book/Report/Conference proceedingChapter

Knight, W, Livingston, RB, Gregory, EJ & McGuire, WL 1977, Absent estrogen receptor and increased recurrence rate in breast cancer. in Proceedings of the American Association for Cancer Research. vol. Vol. 18.
Knight W, Livingston RB, Gregory EJ, McGuire WL. Absent estrogen receptor and increased recurrence rate in breast cancer. In Proceedings of the American Association for Cancer Research. Vol. Vol. 18. 1977
Knight, W. ; Livingston, Robert B ; Gregory, E. J. ; McGuire, W. L. / Absent estrogen receptor and increased recurrence rate in breast cancer. Proceedings of the American Association for Cancer Research. Vol. Vol. 18 1977.
@inbook{1b2efcb8a82e4891990a50ab06a7617c,
title = "Absent estrogen receptor and increased recurrence rate in breast cancer",
abstract = "Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17{\%}): 11/34 ER- and 8/79 ER+ pts., (32 vs 10{\%}, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34{\%}); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42{\%}); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20{\%}). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17{\%}) as in Stage II, ER+ pts. (5/33 or 15{\%}). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.",
author = "W. Knight and Livingston, {Robert B} and Gregory, {E. J.} and McGuire, {W. L.}",
year = "1977",
language = "English (US)",
volume = "Vol. 18",
booktitle = "Proceedings of the American Association for Cancer Research",

}

TY - CHAP

T1 - Absent estrogen receptor and increased recurrence rate in breast cancer

AU - Knight, W.

AU - Livingston, Robert B

AU - Gregory, E. J.

AU - McGuire, W. L.

PY - 1977

Y1 - 1977

N2 - Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17%): 11/34 ER- and 8/79 ER+ pts., (32 vs 10%, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34%); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42%); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20%). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17%) as in Stage II, ER+ pts. (5/33 or 15%). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.

AB - Estrogen receptors (ER) were determined as positive (ER+) or negative (ER-) on tissue from primary tumors in 113 women with operable breast cancer. All had mastectomy and axillary node dissection by the same surgeons, without knowledge of receptor status. Recurrences are documented in 19(17%): 11/34 ER- and 8/79 ER+ pts., (32 vs 10%, p < .01) with mean followup of 16 months in each group. Higher recurrence rates in ER- pts. appear independent of these factors: pathologic stage (I, 3/18 ER- vs 3/45 ER+; II, 8/17 ER- vs 5/33 ER+, p < .05); adjuvant therapy (3/9 ER- vs 1/16 ER+); and postoperative radiotherapy (9/20 ER- vs 4/33 ER+, p < .05). ER- pts. tend to be younger (mean age, 50 vs 60), but no significant differences were seen in proportion of Stage I vs. II pts. who were ER- (29 vs 34%); fraction of ER- vs ER+ pts. who received radiotherapy (59 vs 42%); or fraction of ER- vs ER+ pts. who received adjuvant therapy (26 vs 20%). Frequency of modified vs classical radical mastectomy, of medial quadrant lesions, and of T3 lesions was similar in the 2 groups. Recurrence was as frequent in Stage I, ER- pts. (3/18 or 17%) as in Stage II, ER+ pts. (5/33 or 15%). Conclusion: Lack of ER in the primary breast tumor is a newly defined factor of major prognostic impact in pts. undergoing mastectomy.

UR - http://www.scopus.com/inward/record.url?scp=0017694717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017694717&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0017694717

VL - Vol. 18

BT - Proceedings of the American Association for Cancer Research

ER -